YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas
Matrix Metalloproteinase 9
YKL-40 and MMP-9 can be monitored in patients' serum and help confirm the absence of active disease in GBM and YKL-40 in anaplastic glioma patients. YKL-40 can be used as predictor of survival in patients with high-grade glioma. Longitudinal studies with a larger patient population are needed to confirm these findings.